Browse Results

  • Division: : Cancer Center
  • Therapeutic Area: Leukemia, Lymphoma, and Myeloma


There are 31 clinical trial(s) matching your criteria.

Back

Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous Leukemia

Investigator: Ronan Swords

Institutional Protocol #: 20151147

National Clinical Trials Identifier: NCT02610777

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase II

Enrolling Since: 7/11/2016

1138131 A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), A Novel Inhibitor of Aurora Kinase A, in Adult Patients with Relapsed/Refractory Acute Megakaryoblastic Leukemia or Myelofibrosis (Including Primary and Post-Essential/Post- Polycythemic Myelofibrosis)

Investigator: Ronan Swords

Institutional Protocol #: 20151074

National Clinical Trials Identifier: NCT02530619

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase I

Enrolling Since: 6/24/2016

A 1-Year Multicenter, Randomized, Open-Label Controlled Study to Evaluate the Efficacy and Safety of Umbilical Cord Blood Cells Expanded Ex Vivo with Mesenchymal Precursor Cells for Hematopoietic Recovery in Patients With Hematologic Malignancies After Myeloablative Conditioning

Investigator: Denise Pereira

Institutional Protocol #: 20140789

National Clinical Trials Identifier: NCT01854567

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase III

Enrolling Since: 9/10/2015

Back